Stockscreener 앱 받기
7.675
1.60%
-0.125
전일 마감가:
$7.80
열려 있는:
$7.82
하루 거래량:
750.16K
Relative Volume:
0.15
시가총액:
$1.62B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-42.64
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
+0.59%
1개월 성능:
+7.19%
6개월 성능:
-14.91%
1년 성능:
-1.98%
1일 변동 폭
$7.655
$7.90
1주일 범위
$7.52
$7.90
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.675 | 1.64B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
125.52 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.01 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.54 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
489.92 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Will BioCryst Pharmaceuticals Inc. stock beat EPS estimatesRisk Management Strategies & Invest Smarter With Signals - bollywoodhelpline.com
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Charlie Gayer to be BioCryst CEO effective January 1 - The Pharma Letter
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says - marketscreener.com
Rice Hall James & Associates LLC Sells 179,891 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Price-Driven Insight from (BCRX) for Rule-Based Strategy - Stock Traders Daily
Trade Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Market Sentiment & Advanced Technical Signal Analysis - moha.gov.vn
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Alane Barnes Sells 21,773 Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
1-year trial data: Orladeyo cuts swelling attacks in young children - Angioedema News
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 - Insider Monkey
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Volume Leaders & AI Optimized Trade Strategies - Улправда
Is BioCryst Pharmaceuticals Inc. stock supported by strong fundamentalsBond Market & Short-Term High Return Strategies - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Published on: 2025-12-19 20:19:26 - ulpravda.ru
Will BioCryst Pharmaceuticals Inc. stock deliver strong dividend growthGold Moves & Free Community Supported Trade Ideas - DonanımHaber
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Selloffs & Expert Curated Trade Setup Alerts - DonanımHaber
What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
ETF Watch: What is the fair value of BioCryst Pharmaceuticals Inc. stock now2025 Support & Resistance & Safe Capital Growth Stock Tips - DonanımHaber
EDGAR Filing Documents for 0001140361-25-046040 - SEC.gov
Astria Therapeutics (NASDAQ: ATXS) details terms of BioCryst merger and special vote - Stock Titan
BioCryst Pharmaceuticals (BCRX) details cash and stock deal to acquire Astria - Stock Titan
Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zone2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Published on: 2025-12-18 17:50:37 - ulpravda.ru
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (BCRX) officer reports 8,181-share tax withholding - Stock Titan
Q4 Earnings Estimate for BCRX Issued By HC Wainwright - MarketBeat
BioCryst Pharmaceuticals (BCRX) CLO reports tax withholding and share sale - Stock Titan
CEO Stonehouse Surrenders 27,368 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView — Track All Markets
BioCryst Pharmaceuticals (NASDAQ: BCRX) CEO reports tax share withholding - Stock Titan
BioCryst Pharma stock price target raised to $32 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Bullish Estimate for BCRX FY2025 Earnings - MarketBeat
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? - Yahoo Finance
FDA extends Orladeyo approval to children as young as 2 - Angioedema News
BCRX: HC Wainwright Maintains Buy Rating, Raises Price Target to $32 | BCRX Stock News - GuruFocus
HC Wainwright Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - MarketBeat
Officer Barnes Files To Sell 21,210 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView — Track All Markets
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval By Investing.com - Investing.com Nigeria
BioCryst Pharma stock rating reiterated by Citizens on pediatric approval - Investing.com Nigeria
BioCryst releases preliminary 2024 results, 2025 guidance - MSN
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 - sharewise.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
The Technical Signals Behind (BCRX) That Institutions Follow - news.stocktradersdaily.com
Aug Highlights: Is BioCryst Pharmaceuticals Inc stock oversold or undervaluedJuly 2025 Sentiment & Risk Controlled Swing Alerts - moha.gov.vn
FDA approves BioCryst’s oral pellet version of rare disease drug for children - WKZO
Alkeon Capital Management LLC Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.87%
자본화:
|
볼륨(24시간):